Drugs Made In America Acquisition Corp. (DMAA) Announces Definitive Merger Agreement with Power Analytics Global Corp (PAGC)

Key Highlights of the Report

• Definitive Merger Agreement Signed: DMAA, a publicly-traded SPAC, has entered into a binding merger agreement with Power Analytics Global Corp (PAGC), a private AI and analytics company.
• Targeted Enterprise Value: The transaction aims for a PAGC enterprise value of \$1 billion at closing, subject to milestone achievements and a valuation floor.
• Minimum Cash Condition and PIPE Financing: DMAA and PAGC have set a target to deliver at least \$30 million in cash at closing (with flexibility to close no lower than \$15 million), sourced from DMAA’s trust account and/or PIPE (Private Investment in Public Equity) financing. The final valuation, ownership split, and execution plan will be adjusted based on the actual cash delivered at close.
• Valuation Milestone Schedule: The ultimate enterprise value and equity issued will be adjusted based on cash delivered at closing, ranging from \$300 million to \$1 billion, depending on the funding level achieved.
• Shareholder and Regulatory Approvals: The transaction is subject to DMAA stockholder approval, SEC review (including a Form S-4 registration statement), and other customary closing conditions.
• Forward-looking Statements: The company has included customary forward-looking statement disclaimers regarding the expected benefits, timing, and risks of the transaction.

Detailed Transaction Terms

• Merger Structure:
  • At closing, all outstanding shares of PAGC will convert into shares of the new public company (“NEWCO”) at an exchange ratio to be determined by the final prospectus/registration statement with the SEC.
  • The merger agreement includes mechanisms to adjust the number of shares issued and ownership percentages, based on the final cash delivered at close and PIPE financing.
• Valuation and Milestones:
  • The PAGC enterprise value will be set on a sliding scale, based on the cash delivered at closing:
  • \$15M – \$25M cash: \$300 million enterprise value
  • \$25M – \$50M cash: Up to \$500 million enterprise value
  • \$50M – \$75M cash: Up to \$750 million enterprise value
  • \$75M+ cash (or full execution): \$1 billion enterprise value (target)
  • Final equity allocation between DMAA and PAGC shareholders will be mutually agreed, subject to dilution by any PIPE issuances.
  • No fractional shares will be issued; cash will be paid in lieu of any fractional share amounts.
• PIPE Financing:
  • DMAA is authorized to pursue PIPE financing to meet the minimum cash requirement and fund the merged entity.
  • PIPE investors (accredited and institutional) will participate on terms to be set prior to closing, with resulting dilution to both DMAA and PAGC shareholders.
• Conditions to Closing:
  • Approval by DMAA stockholders after filing and SEC effectiveness of a Form S-4 registration statement.
  • PAGC must provide evidence of commercial traction, including binding revenue contracts with customers.
  • PAGC to provide audited financial statements for the two most recent fiscal years and any available interim periods, prepared in accordance with GAAP or IFRS.
  • All required regulatory, SEC, and stock exchange approvals must be obtained.
• Termination Rights:
  • If minimum cash and other closing conditions are not met, the parties reserve the right to terminate the merger agreement.
• Representations, Warranties, and Covenants:
  • The agreement contains extensive representations and warranties from both DMAA and PAGC, including absence of material adverse changes, compliance with laws, and no undisclosed broker fees.
  • Both parties commit to use commercially reasonable efforts to finalize the transaction, including the execution of further documents and cooperation in regulatory filings.

Important and Potentially Price-Sensitive Information for Shareholders

• Valuation Sensitivity: The final valuation of PAGC, and the resulting dilution or ownership for existing DMAA shareholders, will depend directly on the actual cash delivered at closing, which is in turn dependent on redemptions and PIPE financing. If the minimum cash target is not met, the valuation and ownership split will be adjusted downward, or the deal may not proceed.
• PIPE Financing and Dilution: Any PIPE financing will dilute both DMAA and PAGC shareholders. The terms and amount of PIPE financing are not yet finalized and could significantly impact post-merger ownership and market capitalization.
• Regulatory and SEC Review: The merger is subject to SEC review of the registration statement and shareholder approval, which introduces timing and completion risks. Any delay or non-approval could materially impact DMAA’s share price.
• Forward-Looking Statements: The agreement includes forward-looking statements about the benefits, timing, and outcome of the merger, which are subject to significant uncertainties and risks. Investors should not rely on these statements as guarantees of future performance.
• No Proxy Solicitation or Offer Yet: No offer or solicitation is being made in this filing; any offer of securities will only be made via a prospectus meeting the requirements of the Securities Act and in accordance with applicable law.

Conclusion

The DMAA–PAGC merger represents a potentially transformative transaction for DMAA shareholders, with the possibility of creating a major AI and analytics public company. The targeted \$1 billion enterprise value and associated conditions could drive significant market interest and price movement, but are subject to funding, regulatory, and execution risks. Shareholders are strongly advised to monitor SEC filings, especially the forthcoming S-4 registration statement, for definitive terms, dilution impacts, and risk factors.

Shareholders and investors should assess the evolving details carefully, as the final terms will only be set closer to the closing, depending on cash delivered, PIPE participation, and regulatory approvals—all of which are highly material to DMAA’s valuation and future prospects.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any security. The transaction described is subject to numerous conditions and risks, including but not limited to regulatory approval, market conditions, and final negotiation of key terms. Investors should review all SEC filings and consult their own advisors before making investment decisions. No warranty is made as to the accuracy or completeness of the information contained herein.

View Drugs Made In America Acquisition Corp. Historical chart here